WEBULL
News
CANF
4.340
+2.84%
0.120
Can-Fite BioPharma Wins Canadian Patent Allowance for Namodenoson Obesity Use
TipRanks · 1d ago
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
TipRanks · 1d ago
Can-Fite BioPharma Secures Canadian Patent Allowance For A3 Adenosine Receptor Ligand Targeting Fat Loss
Benzinga · 1d ago
Can-Fite BioPharma Receives Canadian Patent Allowance for Namodenoson as Anti-Obesity Therapy
Reuters · 1d ago
Can-Fite BioPharma erhält kanadische Patenterlaubnis für Namodenoson als Anti-Obesitas-Therapie
Reuters · 1d ago
Weekly Report: what happened at CANF last week (0202-0206)?
Weekly Report · 1d ago
Can-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
TipRanks · 5d ago
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
TipRanks · 5d ago
Can-Fite BioPharma Announces Patient With Advanced Decompensated Liver Cirrhosis Underwent Liver Transplantation Following Treatment With Namodenoson
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 5d ago
Can-Fite BioPharma Reports Clinical Stabilization in Decompensated Liver Cirrhosis Patient Treated with Namodenoson
Reuters · 5d ago
Can-Fite BioPharma meldet erfolgreichen Einsatz von Namodenoson als Brücke zur Lebertransplantation bei dekompensierter Leberzirrhose
Reuters · 5d ago
Weekly Report: what happened at CANF last week (0126-0130)?
Weekly Report · 02/02 09:40
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
TipRanks · 01/27 21:47
Weekly Report: what happened at CANF last week (0119-0123)?
Weekly Report · 01/26 09:40
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
TipRanks · 01/20 12:27
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
TipRanks · 01/20 12:10
Can-Fite BioPharma Completes Enrollment in Phase 2a Pancreatic Cancer Trial
Reuters · 01/20 12:00
CAN FITE BIOPHARMA LTD: PRIMARY SAFETY ENDPOINT DEMONSTRATED TO DATE; TOP-LINE EFFICACY DATA EXPECTED IN Q3 2026
Reuters · 01/20 12:00
Weekly Report: what happened at CANF last week (0112-0116)?
Weekly Report · 01/19 09:44
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.